Arecor and Sequel Med Tech to host fireside panel
Arecor Therapeutics plc and Sequel Med Tech LLC are co-hosting a virtual panel discussion on January 7th, featuring key opinion leaders in diabetes care to discuss innovation in the insulin pump market and the treatment journey for individuals with diabetes. The discussion will highlight Arecor's AT278 ultra-concentrated, ultra-rapid insulin and Sequel's twiist device, focusing on their co-development and the future of automated insulin delivery systems. This event aims to explore advancements that can reduce the daily management burden and improve outcomes for people with diabetes on intensive insulin therapy.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
- Key Opinion Leader commentary on the treatment journey for people with diabetes and factors driving future innovation
- Discussion around Arecor and Sequel's next generation insulin-AID system co-development deal; what's next for the future of the insulin/pump market
Cambridge, UK, 9 December 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on Wednesday 7 January at 16:00 GMT / 11:00 ET / 08:00 PT.
Speakers will include Dr Sarah Howell, CEO of Arecor, Dr Alan Lotvin, MD, CEO and Co-Founder of Sequel, and Thomas Blevins MD, FACE, FNLA, Endocrinologist and Key Opinion Leader on the Diabetes sector. The session will be chaired by Melanie Senior, Healthcare Writer and Analyst.
Topics to be discussed include the treatment journey for people with diabetes and the healthcare professional's experience; the current diabetes AID system market and the factors driving innovation; Arecor's AT278 ultra-concentrated, ultra-rapid insulin in development; Sequel's twiist device and its launch in the US; the next steps for both companies as they co-develop AT278 and the twiist device. Finally, a discussion about what's next for the diabetes / insulin pump sector; what are people with diabetes on intensive insulin therapy looking for in order to lower the daily management burden and improve outcomes. The session will conclude with a Q&A session.
To register for the event, please email arecor@vigoconsulting.com or Investors@SequelMedTech.com.
About AT278
About Sequel Med Tech
Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit www.sequelmedtech.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.